T Cells As Vehicles for Cancer Vaccination

Overview

Journal J Biomed Biotechnol

Specialty Biology

Date 2011 Dec 2

PMID 22131805

Citations 7

Authors

Adham S Bear

Conrad R Cruz

Aaron E Foster

Affiliations

Soon will be listed here.

Abstract

The success of cancer vaccines is dependent on the delivery of tumor-associated antigens (TAAs) within lymphoid tissue in the context of costimulatory molecules and immune stimulatory cytokines. Dendritic cells (DCs) are commonly utilized to elicit antitumor immune responses due to their attractive costimulatory molecule and cytokine expression profile. However, the efficacy of DC-based vaccines is limited by the poor viability and lymph-node migration of exogenously generated DCs in vivo. Alternatively, adoptively transferred T cells persist for long periods of time in vivo and readily migrate between the lymphoid and vascular compartments. In addition, T cells may be genetically modified to express both TAA and DC-activating molecules, suggesting that T cells may be ideal candidates to serve as cellular vehicles for antigen delivery to lymph node-resident DCs in vivo. This paper discusses the concept of using T cells to induce tumor-specific immunity for vaccination against cancer.

Citing Articles

Novel Targeting to XCR1 Dendritic Cells Using Allogeneic T Cells for Polytopical Antibody Responses in the Lymph Nodes.

Kitazawa Y, Ueta H, Sawanobori Y, Katakai T, Yoneyama H, Ueha S Front Immunol. 2019; 10:1195.

PMID: 31191552 PMC: 6548820. DOI: 10.3389/fimmu.2019.01195.

Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo.

ONeil R, Saha S, Veach R, Welch R, Woodard L, Rooney C Nat Commun. 2018; 9(1):1325.

PMID: 29636469 PMC: 5893599. DOI: 10.1038/s41467-018-03787-8.

Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.

Tanemura M, Miyoshi E, Nagano H, Eguchi H, Matsunami K, Taniyama K World J Gastroenterol. 2015; 21(40):11396-410.

PMID: 26523105 PMC: 4616216. DOI: 10.3748/wjg.v21.i40.11396.

Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.

Tanaka T, Kitamura H, Inoue R, Nishida S, Takahashi-Takaya A, Kawami S Clin Dev Immunol. 2013; 2013:262967.

PMID: 24363758 PMC: 3863714. DOI: 10.1155/2013/262967.

Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.

Youlin K, Li Z, Xin G, Mingchao X, Xiuheng L, Xiaodong W Hum Vaccin Immunother. 2013; 9(4):766-72.

PMID: 23295983 PMC: 3903894. DOI: 10.4161/hv.23116.

References

Tacken P, de Vries I, Torensma R, Figdor C . Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007; 7(10):790-802. DOI: 10.1038/nri2173. View

Mauri D, Wyss-Coray T, Gallati H, Pichler W . Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules. J Immunol. 1995; 155(1):118-27. View

Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay C . Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol. 1998; 28(9):2760-9. DOI: 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N. View

Poulin L, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen J . Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010; 207(6):1261-71. PMC: 2882845. DOI: 10.1084/jem.20092618. View

Petersen T, Sika-Paotonu D, Knight D, Simkins H, Hermans I . Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines. PLoS One. 2011; 6(3):e17657. PMC: 3069042. DOI: 10.1371/journal.pone.0017657. View

Bates J, Uematsu S, Akira S, Mizel S . Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol. 2009; 182(12):7539-47. PMC: 3770462. DOI: 10.4049/jimmunol.0804225. View

Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre C, Ventre E . The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med. 2010; 207(6):1283-92. PMC: 2882835. DOI: 10.1084/jem.20100223. View

Ma D, Clark E . The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol. 2009; 21(5):265-72. PMC: 2749083. DOI: 10.1016/j.smim.2009.05.010. View

Stevanovic S . Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer. 2002; 2(7):514-20. DOI: 10.1038/nrc841. View

10.

Aarntzen E, Figdor C, Adema G, Punt C, de Vries I . Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother. 2008; 57(10):1559-68. PMC: 2491428. DOI: 10.1007/s00262-008-0553-y. View

11.

Azuma M, Yssel H, Phillips J, Spits H, Lanier L . Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med. 1993; 177(3):845-50. PMC: 2190946. DOI: 10.1084/jem.177.3.845. View

12.

Liu B, Dai J, Zheng H, Stoilova D, Sun S, Li Z . Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci U S A. 2003; 100(26):15824-9. PMC: 307652. DOI: 10.1073/pnas.2635458100. View

13.

Russo V, Cipponi A, Raccosta L, Rainelli C, Fontana R, Maggioni D . Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J Clin Invest. 2007; 117(10):3087-96. PMC: 1978420. DOI: 10.1172/JCI30605. View

14.

Wyss-Coray T, Baumann K, Bettens F, Grunow R, Pichler W . The B7 adhesion molecule is expressed on activated human T cells: functional involvement in T-T cell interactions. Eur J Immunol. 1993; 23(9):2175-80. DOI: 10.1002/eji.1830230919. View

15.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

16.

Sancho D, Mourao-Sa D, Joffre O, Schulz O, Rogers N, Pennington D . Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008; 118(6):2098-110. PMC: 2391066. DOI: 10.1172/JCI34584. View

17.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

18.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

19.

Hanau D, Spehner D, Schmid C, Rammensee H, de la Salle H, Schild H . Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999; 162(7):3757-60. View

20.

Todryk S, Melcher A, Hardwick N, Linardakis E, Bateman A, Colombo M . Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol. 1999; 163(3):1398-408. View